INE963

Product vision
  • Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management
MoA
  • Novel and unknown
Key features
  • No cross-resistance
  • No resistant mutants identified
  • Low predicted dose and long predicted human half-life (60 hours)
  • Fast killing in vitro and in vivo
Status
  • Preclinical development
Next milestone
  • Initiate first-in-human study
Previously
  • Discovery partnership with Novartis
  • NVP-INE963. Full reference MMV1582617
MMV Project Director
  • Dr Cristina Donini